Literature DB >> 21647682

Alzheimer disease: are we intervening too late? Pro.

Virginia Olga B Emery1.   

Abstract

The affirmative position is argued in response to the question of whether intervention in the disease course of Alzheimer disease (AD) occurs too late. AD is not a singular, homogeneous disease, but rather a final common pathway or end-point that can be arrived at through multiple routes. As part of the affirmative argument, there is a delineation of two long-term trajectories leading to AD: (1) normal elderly progression to AD, and (2) depressed elderly progression to AD. In documenting normal elderly devolution into AD, two "normal" elderly pre-AD or prodromal stages are discussed: age-associated memory impairment (AAMI) and mild cognitive impairment (MCI). Data are provided evidencing significantly high conversion rates from these pre-AD stages to actual AD. Using the same paradigmatic approach that is used in documenting normal elderly decline into AAMI and MCI with eventual conversion to AD; there is explication of depressed elderly conversion to AD. The long-term, multiphasic disease progression of major depression without dementia to depressive dementia to final conversion to AD is brought into focus as another example of why intervention must occur prior to actual conversion to AD. Depression is defined as a cognitive syndrome and risk factor for AD requiring aggressive targeted intervention. AD does not just come suddenly out of nowhere. First intervention must occur during the pre-AD phases in an attempt to prevent, delay, and interrupt long-term neurodegenerative processes involved in both normal elderly and depressed elderly conversion to AD. A primary strategy proposed is to delay onset of AD. Population statistics indicate that if AD is delayed by a modest 1 year, there would be 9.5 million fewer cases by 2050, resulting in significant reduction in burden of disease. Data show early intervention with cognitive stimulation (mental exercise), physical exercise, aggressive treatment of AD risk factors and excess disability, psychotherapy, and other nonpharmacological interventions in combination with each other and/or with medications can result in delay of onset of AD. First intervention at time of diagnosis of AD is too late, when by definition, final conversion to AD has already occurred. When we have knowledge to successfully intervene earlier, why would we not want to do so.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647682     DOI: 10.1007/s00702-011-0663-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  80 in total

1.  Influence of leisure activity on the incidence of Alzheimer's disease.

Authors:  N Scarmeas; G Levy; M X Tang; J Manly; Y Stern
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

2.  Depression as a risk factor for Alzheimer disease: the MIRAGE Study.

Authors:  Robert C Green; L Adrienne Cupples; Alex Kurz; Sanford Auerbach; Rodney Go; Dessa Sadovnick; Ranjan Duara; Walter A Kukull; Helena Chui; Timi Edeki; Patrick A Griffith; Robert P Friedland; David Bachman; Lindsay Farrer
Journal:  Arch Neurol       Date:  2003-05

3.  Leisure activities and the risk of amnestic mild cognitive impairment in the elderly.

Authors:  J Verghese; A LeValley; C Derby; G Kuslansky; M Katz; C Hall; H Buschke; R B Lipton
Journal:  Neurology       Date:  2006-02-08       Impact factor: 9.910

Review 4.  Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials.

Authors:  Patrick J Smith; James A Blumenthal; Benson M Hoffman; Harris Cooper; Timothy A Strauman; Kathleen Welsh-Bohmer; Jeffrey N Browndyke; Andrew Sherwood
Journal:  Psychosom Med       Date:  2010-03-11       Impact factor: 4.312

5.  Enrichment Effects on Adult Cognitive Development: Can the Functional Capacity of Older Adults Be Preserved and Enhanced?

Authors:  Christopher Hertzog; Arthur F Kramer; Robert S Wilson; Ulman Lindenberger
Journal:  Psychol Sci Public Interest       Date:  2008-10-01

6.  Reduction of orbital frontal cortex volume in geriatric depression.

Authors:  T Lai; M E Payne; C E Byrum; D C Steffens; K R Krishnan
Journal:  Biol Psychiatry       Date:  2000-11-15       Impact factor: 13.382

Review 7.  The interaction of drug- and psychotherapy in the long-term treatment of depression.

Authors:  D J Kupfer; E Frank
Journal:  J Affect Disord       Date:  2001-01       Impact factor: 4.839

8.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

9.  Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.

Authors:  Hélène Amieva; Mélanie Le Goff; Xavier Millet; Jean Marc Orgogozo; Karine Pérès; Pascale Barberger-Gateau; Hélène Jacqmin-Gadda; Jean François Dartigues
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

10.  Structural brain CT changes and cognitive deficits in elderly depressives with and without reversible dementia ('pseudodementia').

Authors:  G D Pearlson; P V Rabins; W S Kim; L J Speedie; P J Moberg; A Burns; M J Bascom
Journal:  Psychol Med       Date:  1989-08       Impact factor: 7.723

View more
  17 in total

1.  Positive argument for debate in J Neural Transmission: Alzheimer's disease: are we intervening too late? Yes, by years if not decades.

Authors:  Thomas B Shea; Ruth Remington
Journal:  J Neural Transm (Vienna)       Date:  2012-07-11       Impact factor: 3.575

2.  The effects of interactions between selenium and zinc serum concentration and SEP15 and SLC30A3 gene polymorphisms on memory scores in a population of mature and elderly adults.

Authors:  Tatiane Jacobsen da Rocha; Cláudia Justin Blehm; Daiani Pires Bamberg; Tainá Ludmila Ramos Fonseca; Luciana Alves Tisser; Alcyr Alves de Oliveira Junior; Fabiana Michelsen de Andrade; Marilu Fiegenbaum
Journal:  Genes Nutr       Date:  2013-12-14       Impact factor: 5.523

3.  Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints.

Authors:  Eric A Macklin; Deborah Blacker; Bradley T Hyman; Rebecca A Betensky
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  The Physical Activity and Alzheimer's Disease (PAAD) Study: Cognitive outcomes.

Authors:  Jennifer L Etnier; William B Karper; Jeffrey D Labban; Aaron T Piepmeier; Chia-Hao Shih; William N Dudley; Vincent C Henrich; Laurie Wideman
Journal:  Ann Behav Med       Date:  2018-02-05

5.  Innovative Research Design Exploring the Effects of Physical Activity and Genetics on Cognitive Performance in Community-Based Older Adults.

Authors:  Jennifer L Etnier; Jeffrey D Labban; William B Karper; Laurie Wideman; Aaron T Piepmeier; Chia-Hao Shih; Michael Castellano; Lauren M Williams; Se-Yun Park; Vincent C Henrich; William N Dudley; Kelli L Rulison
Journal:  J Aging Phys Act       Date:  2015-01-16       Impact factor: 1.961

6.  Serious games for screening pre-dementia conditions: from virtuality to reality? A pilot project.

Authors:  Chiara Zucchella; Elena Sinforiani; Cristina Tassorelli; Elena Cavallini; Daniela Tost-Pardell; Sergi Grau; Stefania Pazzi; Stefano Puricelli; Sara Bernini; Sara Bottiroli; Tomaso Vecchi; Giorgio Sandrini; Giuseppe Nappi
Journal:  Funct Neurol       Date:  2014 Jul-Sep

Review 7.  Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.

Authors:  Maire E Percy; Theo P A Kruck; Aileen I Pogue; Walter J Lukiw
Journal:  J Inorg Biochem       Date:  2011-08-19       Impact factor: 4.155

8.  A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.

Authors:  Davide Bruno; Michel J Grothe; Jay Nierenberg; Henrik Zetterberg; Kaj Blennow; Stefan J Teipel; Nunzio Pomara
Journal:  Neuropsychologia       Date:  2015-01-19       Impact factor: 3.139

9.  CLOCK Genes and Circadian Rhythmicity in Alzheimer Disease.

Authors:  J Thome; A N Coogan; A G Woods; C C Darie; F Häßler
Journal:  J Aging Res       Date:  2011-10-18

10.  Additive toxicity of β-amyloid by a novel bioactive peptide in vitro: possible implications for Alzheimer's disease.

Authors:  Sara Garcia-Ratés; Matthew Lewis; Rosemary Worrall; Susan Greenfield
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.